Fig 1: Graphical representation of changes in the percentage of occurrence of the tested immune checkpoints and their ligands on selected subpopulations of lymphocytes in patients with Vulvar Lichen Sclerosus (VLS) and healthy volunteers (HV). (A) shows the percentage of CD4⁺ T lymphocytes expressing PD-1, (B) the percentage of CD4⁺ T lymphocytes expressing PD-L1, (C) the percentage of CD4⁺ T lymphocytes expressing CTLA-4, (D) the percentage of CD4⁺ T lymphocytes expressing CD200R, and (E) the percentage of CD4⁺ T lymphocytes expressing CD200. Panels (F–J) present CD8⁺ T lymphocytes, where (F) shows the percentage of cells expressing PD-1, (G) PD-L1, (H) CTLA-4, (I) CD200R, and (J) CD200. The last group of panels (K–O) refers to CD19⁺ B lymphocytes, showing (K) the percentage of cells expressing PD-1, (L) PD-L1, (M) CTLA-4, (N) CD200R, and (O) CD200. Abbreviations: *statistically significant results; VLS—Vulvar Lichen Sclerosus; HV—healthy volunteers; PD-1—programmed cell death protein 1; PD-L1—programmed death-ligand 1; CTLA-4—cytotoxic T-lymphocyte-associated protein 4; CD200—cluster of differentiation 200; CD200R—CD200 receptor; CD4⁺—T helper lymphocytes; CD8⁺—cytotoxic T lymphocytes; CD19⁺—B lymphocytes.